Broadly Neutralizing Human Anti-HIV Monoclonal Antibody 10E8 and Related Antibodies Capable of Neutralizing Most HIV-1 Strains


The uses for human anti-HIV monoclonal antibody 10E8 and its variants include passive immunization, therapeutic vaccination, and the development of vaccine immunogens. 10E8 is one of the most potent HIV-neutralizing antibodies isolated and it neutralizes up to 98% of diverse HIV-1 strains. 10E8 is specific to the membrane-proximal external region (MPER) of the HIV envelope protein gp41 and 10E8 is orthogonal to other anti-HIV antibodies. In combination with other antibodies 10E8 may provide an antibody response that neutralizes nearly all strains of HIV-1. Additionally, 10E8 effectively induces antibody-dependent cellular cytotoxicity (ADCC) indicating its potential use for therapeutic vaccine strategies. Further, 10E8 is a tool for immunogen design and validation of immunogen structure.

NIAID is currently developing certain embodiments of 10E8 for clinical use. Therefore, for some fields of use, NIH will evaluate a license applicant's capabilities and experience in advancing similar technologies through the regulatory process. This technology is not eligible for the NIH's start-up license program.

Potential Commercial Applications: Competitive Advantages:
  • Passive protection to prevent HIV infection
  • Passive protection to prevent mother-to-infant HIV transmission
  • Topical microbicide to prevent HIV infection
  • Gene-based vectors for anti-gp41 antibody expression
  • Therapeutic for the elimination of HIV infected cells that are actively producing virus
 
  • One of the most potent Human broadly-neutralizing anti HIV antibodies isolated to date
  • Broad reactivity and high affinity to most HIV-1 strains
  • Activity is highly complementary to existing broadly neutralizing antibodies, such as CD4 binding site antibodies
  • Not auto-reactive


Development Stage:
  • In vitro data available
  • In vivo data available (animal)


Inventors:

John Mascola (NIAID)  ➽ more inventions...

Mark Connors (NIAID)  ➽ more inventions...

Leo Laub (NIAID)  ➽ more inventions...

Jinghe Huang (NIAID)  ➽ more inventions...

Peter Kwong (NIAID)  ➽ more inventions...

Gilad Ofek (NIAID)  ➽ more inventions...

Jiang Zhu (NIAID)  ➽ more inventions...

Gary Nabel (NIAID)  ➽ more inventions...

Rebecca Rudicell (NIAID)  ➽ more inventions...

Ivelin Georgiev (NIAID)  ➽ more inventions...

Yongping Yang (NIAID)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 9,475,862 issued 2016-10-25
US Application No. 15/226,744
US Application No. 61/672,708
US Application No. 61/698,480
PCT Application No. PCT/US2012/063958
US Application No. 14/356,557
US Application No. 15/699,902

Publications:
Huang J, et al. PMID 23151583

Collaboration Opportunity:

The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize 10E8-related vaccines or immunotherapies. For collaboration opportunities, please contact Bill Ronnenberg at +1 240-627-3726 or wronnenberg@niaid.nih.gov.


Licensing Contact:
Christopher Kornak, J.D.
Email: chris.kornak@nih.gov
Phone: 240-627-3705

OTT Reference No: E-253-2011/0
Updated: Jun 18, 2014